Research progress of glucocorticoid receptor in urological malignant tumors

doi:10.3760/cma.j.issn.1673-422X.2017.06.019

Abstract

Abstract: Glucocorticoid receptor (GR), a member of the steroid receptor superfamily, can mediate the signal pathway of ligands like glucocorticoids, regulate the transcription of target genes, and exert biological activity. GR is expressed in different degrees in three major kinds of urological malignant tumors including renal cancer, bladder cancer and prostate cancer. It also affects the metabolism of tumor cells, and is closely related to the occurrence, development and prognosis of tumors. GR provides an important clue for targeted therapy and endocrine therapy of urological malignant tumors.

Key words: Receptors, glucocorticoid, Kidney neoplasms, Urinary bladder neoplasms, Prostatic neoplasms

Zhou Qidong, Jiang Guangliang, Xu Ke. Research progress of glucocorticoid receptor in urological malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 476-.

References

［1］王德杰, 刘兴国, 张东. 糖皮质激素受体的研究进展［J］. 现代生物医学进展, 2010, 10(8): 1592-1594. DOI: 10.13241/j.cnki.pmb.2010.08.001. ［2］ Stechschulte LA, Wuescher L, Marino JS, et al. Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN［J］. J Biol Chem, 2014, 289(25): 17885-17894. DOI: 10.1074/jbc.M113.544072. ［3］ Nicolaides NC, Charmandari E, Chrousos GP, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligandinduced repression of the human glucocorticoid receptor［J］. BMC Endocr Disord, 2014, 14: 71. DOI: 10.1186/147268231471. ［4］ Kassi E, Moutsatsou P. Glucocorticoid receptor signaling and prostate cancer［J］. Cancer Lett, 2011, 302(1): 1-10. DOI: 10.1016/j.canlet.2010.10.020. ［5］ McBeth L, Grabnar M, Selman S, et al. Involvement of the androgen and glucocorticoid receptors in bladder cancer［J］. Int J Endocrinol, 2015, 2015: 384860. DOI: 10.1155/2015/384860. ［6］ Czarnecka AM, Niedzwiedzka M, Porta C, et al. Hormone signaling pathways as treatment targets in renal cell cancer (review)［J］. Int J Oncol, 2016, 48(6): 2221-2235. DOI: 10.3892/ijo.2016.3460. ［7］ Yakirevich E, Matoso A, Sabo E, et al. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study［J］. Hum Pathol, 2011, 42(11): 1684-1692. DOI: 10.1016/j.humpath.2011.01.014. ［8］ Min KJ, Jang JH, Lee JT, et al. Glucocorticoid receptor antagonist sensitizes TRAILinduced apoptosis in renal carcinoma cells through upregulation of DR5 and downregulation of cFLIP(L) and Bcl2［J］. J Mol Med (Berl), 2012, 90(3): 309-319. DOI: 10.1007/s0010901108218. ［9］ Jang JH, Min KJ, Kim S, et al. RU486 induces proapoptotic endoplasmic reticulum stress through the induction of CHOP expression by enhancing C/EBPδ expression in human renal carcinoma caki cells［J］. J Cell Biochem, 2016, 117(2): 361-369. DOI: 10.1002/jcb.25278. ［10］ Huynh TP, Barwe SP, Lee SJ, et al. Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,KATPase beta1 subunit expression［J］. PLoS One, 2015, 10(4): e122442. DOI: 10.1371/journal.pone.0122442. ［11］ Arai Y, Nonomura N, Nakai Y, et al. The growthinhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro［J］. Cancer Invest, 2008, 26(1): 35-40. DOI:10.1080/07357900701638418. ［12］ Zheng Y, Izumi K, Li Y, et al. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasonemediated glucocorticoid receptor signals［J］. Mol Cancer Ther, 2012, 11(12): 2621-2632. DOI: 10.1158/15357163.MCT120621. ［13］ Ishiguro H, Kawahara T, Zheng Y, et al. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity［J］. Cancer Chemother Pharmacol, 2014, 74(2): 249-255. DOI: 10.1007/s0028001424967. ［14］ Zheng Y, Ishiguro H, Ide H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression［J］. Mol Endocrinol, 2015, 29(10): 1486-1497. DOI: 10.1210/me.20151128. ［15］ Lesovaya E, Yemelyanov A, Kirsanov K, et al. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies［J］. Cell Cycle, 2013, 12(1): 133-144. DOI: 10.4161/cc.23048. ［16］ Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract［J］. Cancer Biol Ther, 2016, 17(11): 1188-1196. DOI: 10.1080/15384047.2016.1235667. ［17］ Ishiguro H, Kawahara T, Zheng Y, et al. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression［J］. Am J Clin Pathol, 2014, 142(2): 157-164. DOI: 10.1309/AJCPU8UCEZYG4WTV. ［18］ McBeth L, Nwaneri AC, Grabnar M, et al. Glucocorticoid receptor beta increases migration of human bladder cancer cells［J］. Oncotarget, 2016, 7(19): 27313-27324. DOI: 10.18632/oncotarget.8430. ［19］ Nwaneri AC, McBeth L, Hinds TD Jr. SweetP inhibition of glucocorticoid receptor β as a potential cancer therapy［J］. Cancer Cell Microenviron, 2016, 3(3). pii: e1362. ［20］ Hu J, Chen Q. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside［J］. Int Urol Nephrol, 2016, 49(3): 369-380. DOI: 10.1007/s1125501614768. ［21］ Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgentargeted therapy in prostate cancer［J］. Horm Cancer, 2014, 5(2): 72-89. DOI: 10.1007/s1267201401732. ［22］ Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade［J］. Cell, 2013, 155(6): 1309-1322. DOI: 10.1016/j.cell.2013.11.012. ［23］ Xie N, Cheng H, Lin D, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors［J］. Int J Cancer, 2015, 136(4): E27-E38. DOI: 10.1002/ijc.29147. ［24］ Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers［J］. Sci Transl Med, 2015, 7(305): 305ps19. DOI: 10.1126/scitranslmed.aac7531. ［25］ Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer［J］. Sci Transl Med, 2014, 6(254): 254ra125. DOI: 10.1126/scitranslmed.3009448.

[1]	Zhao Xin, Fan Xuewu, Tian Long, Hu Yimin. Application and evaluation study of 3D ultrasound in image guided radiotherapy for prostate cancer [J]. Journal of International Oncology, 2024, 51(1): 43-49.
[2]	Qian Weiwei, Xu Shen, Kong Qi. Differential diagnosis value of D-dimer before operation in renal oncocytoma and chromophobe renal cell carcinoma [J]. Journal of International Oncology, 2023, 50(10): 614-617.
[3]	Xu Xi, Gao Hongliang, Liu Xiang, Zhang Zhensheng, Xu Chuanliang. Correlations between different pH values in tumor microenvironment and bladder cancer [J]. Journal of International Oncology, 2022, 49(11): 696-609.
[4]	Wang Ziyi, Chen Hongjie, Yang Ninggang, Zhang Jun, Zhang Xiangjun, Yu Xinning, Ma Zhongyi, Dai Enlai. Effects of decorin on proliferation, migration and invasion of bladder cancer cells [J]. Journal of International Oncology, 2021, 48(6): 335-340.
[5]	Du Xiao, Zhou Juying. Stereotactic body radiotherapy for localized prostate cancer [J]. Journal of International Oncology, 2021, 48(5): 313-316.
[6]	Zhang Xiaofei, Hu Jianpeng, Cui Feilun. Mechanism of long non-coding RNA in prostate cancer [J]. Journal of International Oncology, 2021, 48(2): 117-120.
[7]	Wu Guang, Yu Yuandong, Chen Ping. Clinical observation of apatinib mesylate in the treatment of metastatic renal carcinoma [J]. Journal of International Oncology, 2021, 48(11): 655-659.
[8]	Wang Jiali, Han Dong, Chen Ying, Zhang Yamin, Ai Meimei. Construction of a nomogram of overall survival of patients with clear cell renal cell carcinoma based on preoperative CT findings [J]. Journal of International Oncology, 2020, 47(8): 480-486.
[9]	Ji Chundong, Liu Kai, Feng Yue, Wang Fei, Yang Jun, Xue Rongbo. Predictive value of PSAMR combined with PI-RADS v2 score in high-grade prostate cancer [J]. Journal of International Oncology, 2020, 47(12): 723-727.
[10]	Han Jing, Yuan Shuai, Pu Yan, Liu Huibin. Analysis of SKA1 gene expression in clear cell renal cell carcinoma and its clinical significance based on bioinformatics database [J]. Journal of International Oncology, 2020, 47(10): 598-605.
[11]	Zhang Jiawei, Wu Jianchen. Application of exosomes in prostates cancer [J]. Journal of International Oncology, 2020, 47(10): 634-636.
[12]	Chen Liang, Peng Min, Weng Yiming, Song Qibin. New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming [J]. Journal of International Oncology, 2019, 46(7): 443-446.
[13]	Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong. Molecular targeted therapy for advanced kidney cancer [J]. Journal of International Oncology, 2019, 46(12): 705-710.
[14]	Cai Liang, Shen Yali. Application of stereotactic body radiation therapy in advanced renal cell carcinoma [J]. Journal of International Oncology, 2019, 46(10): 627-630.
[15]	XU Yao-Zong, GU Xiao, WANG Fei, DING Xue-Fei. Molecular mechanisms of castrationresistant prostate cancer progressed from prostate cancer by androgen deprivation treatment [J]. Journal of International Oncology, 2018, 45(8): 506-509.